Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the GenMark investigation page on our website www.glancylaw.com/case/genmark-diagnostics-inc.

On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.

On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased GenMark securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.